Bowen Matthew
Principal Accounting Officer
Bowen Matthew has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Oct 6, 2026.
On the most recent filing, Bowen Matthew is listed as Principal Accounting Officer at Monte Rosa Therapeutics, Inc. Inside the rolling window, Bowen Matthew reported no open-market purchases and 1 open-market sale totaling $137 in GLUE.
Companies traded
Other insiders at GLUE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$137
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Bowen Matthew made?
Bowen Matthew has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Bowen Matthew trade?
Bowen Matthew has filed SEC Form 4 disclosures for 1 company, including GLUE.
When was Bowen Matthew's most recent SEC Form 4 filing?
Bowen Matthew's most recent SEC Form 4 filing on Tracefour is dated Oct 6, 2026.
What is Bowen Matthew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Bowen Matthew is listed as Principal Accounting Officer.
What is Bowen Matthew's total buy and sell value in the current window?
Inside the rolling retention window, Bowen Matthew bought $0 and sold $137 based on SEC Form 4 filings.
What was Bowen Matthew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13 GLUE shares on 2026-10-05, worth $137, per SEC Form 4 filings.